Modulation of Human Myocardial Metabolism by GLP-1 Dose Response

Exclusion Criteria

• •Chronic illnesses or infections (other than type 2 diabetes)
• •Known coronary artery disease or abnormal ECG on screening evaluation
• •Blood pressure \> 160/100 mmHg on two occasions during screening evaluations. Current use of 3 or fewer blood pressure medications with blood pressure below this cutpoint will be acceptable.
• •Total cholesterol \> 240 mg/dL. Current use of 2 or fewer lipid lowering agents with cholesterol below this cutpoint will be acceptable.
• •Diabetic subjects: Treatment with a GLP-1 agonist or DPP4 inhibitor within the past 6 months
• •Known intolerance to injected GLP-1 agonist
• •Treatment with PPAR gamma agonists currently or within the past 6 months
• •Recognized microvascular complications (retinopathy, nephropathy, neuropathy)
• •Unwillingness or inability to use injected insulin for the purposes of this study
• •Chronic pain or other physical conditions which limit ability to remain supine for the duration of the study protocol
• •History of claustrophobia, musculoskeletal or other factors which would result in an inability to comfortably remain within PET scanner gantry for the duration of the imaging protocol
• •Occupational, investigational or other known radiation exposure which, together with the planned radiologic studies, will result in greater than 500 mrem total exposure in a contiguous 12 month period
• •For female participants, current pregnancy